Oxaliplatin Boosts Survival in Stage III CRC Only Up to 70 Years, Study Finds

A study finds 70 years may be a key cutoff for oxaliplatin benefit in stage III colorectal cancer, with no survival advantage seen in older patients or those with stage II disease.